尿液肽生物标志物组合与慢性肾脏病患者eGFR改善相关
该研究利用毛细管电泳-质谱联用技术分析不同肾脏疾病患者的尿液肽组,在开发队列中比较稳定与eGFR改善患者的肽谱,构建了基于支持向量机的分类组合,并在验证队列中取得AUC 0.85(灵敏度81%、特异度81%)。组合中78%的肽来源于不同类型胶原。
要点
- 尿液肽组合可区分eGFR随时间改善的CKD患者,AUC 0.85。
- 组合中78%的肽段来源于胶原,提示基质重构可能参与肾功能改善。
- 该工具或有助于患者分层,指导更特异或更温和的治疗。
核心结论
- 开发出可区分eGFR随时间改善的CKD患者的尿液肽标志物组合。
研究设计与样本
- 采用CE-MS评估不同肾脏疾病患者的尿液肽组,开发队列与验证队列共纳入稳定(斜率/年-1.5%至+1.5%)376例和eGFR改善(斜率/年>5%)177例患者。
主要发现
- 开发队列中比较稳定与肾功能改善患者,检测到384个显著肽片段。
- 其中141个具有氨基酸序列信息的肽用于构建支持向量机分类组合。
- 验证队列中组合AUC为0.85,灵敏度81%,特异度81%。
- 诊断组合中78%的肽来源于不同类型胶原。
关键数值与推荐
- 稳定组定义:eGFR斜率/年在-1.5%至+1.5%之间(376例)。
- 改善组定义:eGFR斜率/年>5%(177例)。
- 验证队列AUC 0.85(灵敏度81%,特异度81%)。
临床怎么用
- 该尿液肽组合可用于识别eGFR可能改善的CKD患者,辅助分层并考虑更特异或更温和的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An improvement in the glomerular filtration rate (GFR) of chronic kidney disease patients has been an underestimated clinical outcome. Although this may be considered as an unexpected disease course, it may provide some insights into possible mechanisms underlying disease remission and/or regression. Therefore, our aim was to identify urinary peptide biomarkers associated with an improvement in estimated GFR (eGFR) over time and to improve patient stratification. METHODS: Capillary electrophoresis coupled with mass spectrometry (CE-MS) was employed to evaluate the urine peptidome of patients with different types of renal diseases. In total, 376 patients with a slope/year between -1.5% and +1.5% were designated as non-progressors or stable, while 177 patients with a > 5% slope/year were designated as patients with an improved eGFR for state-of-art biomarker discovery and validation. RESULTS: We detected 384 significant peptide fragments by comparing the CE-MS data of the stable patients and those with improved renal function in our development cohort. Of these 384, a set of 141 peptides with available amino acid sequence information were used to generate a support vector machine-based classification panel. The biomarker panel was applied to our validation cohort, achieving a moderate area under the curve (AUC) value of 0.85 (81% sensitivity and 81% specificity). The majority of the peptides (78%) from the diagnostic panel arose from different types of collagen. CONCLUSIONS: We have developed a panel of urinary peptide markers able to discriminate those patients predisposed to improve their kidney function over time and possibly be treated with more specific or less aggressive therapy.
引用
- Markoska K, Pejchinovski M, Pontillo C, et al. Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients. Nephrol Dial Transplant. 2018. PMID: 28992073. doi:10.1093/ndt/gfx263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。